Tag: CAR-T
Tmunity and Oncora Medical Partner to Advance the Use of Real-World...
Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today...
Creative Biolabs Announced Bio-distribution Analysis Services for CAR-T Cell Therapy
Creative Biolabs, a frontier biotech service provider that offers high-quality antibody products, announced today their preclinical viability and bio-distribution analysis services for CAR-T cell...
First systematic study of infections after CAR T-cell therapy
In the first systematic study of its kind, researchers at Fred Hutchinson Cancer Research Center report comprehensive data on infectious complications of an emerging cancer immunotherapy...
FDA Grants Breakthrough Therapy Designation to Novartis’s CAR-T Cell Therapy CTL019
The FDA granted a breakthrough therapy designation to Novartis’s CTL019, a chimeric antigen receptor T cell immunotherapy, or CAR-T, for the treatment of adult...
Immune cell therapy shows promising results for lymphoma patients
Results from phase I trial using CAR-T therapy with axicabtagene ciloleucel (KTE-C19) show durable complete remission in highly refractory diffuse large B-cell lymphoma patients
TAMPA,...
Helix BioPharma Corp. announces the signing of a non-binding letter of...
Helix BioPharma Corp., a clinical stage immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced that it has signed a...